This is a summary of the European public assessment report (EPAR) for Exelon. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Exelon.
Therapeutic Indication
### Therapeutic indication Symptomatic treatment of mild to moderately severe Alzheimer's dementia. Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.
Therapeutic Area (MeSH)
N/AATC Code
N06DA03
ATC Item
rivastigmine
Pharmacotherapeutic Group
Psychoanaleptics
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| rivastigmine | N/A | 利斯的明 |
EMA Name
Exelon
Medicine Name
Exelon
Aliases
N/ANo risk management plan link.
